Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 9 (September)

1. Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy.
   J Clin Oncol, 23(25): 6054-62. [Abstract] [Full-text]
2. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.
   J Clin Oncol, 23(25): 6043-53. [Abstract] [Full-text]
3. Skin biopsy rates and incidence of melanoma: population based ecological study.
   BMJ, 331(7515): 481. [Abstract] [Full-text]
4. Intermittent and chronic ultraviolet light exposure and uveal melanoma: a meta-analysis.
   Ophthalmology, 112(9): 1599-607. [Abstract] [Full-text]
5. Forecasting the prognosis of choroidal melanoma with an artificial neural network.
   Ophthalmology, 112(9): 1608. [Abstract] [Full-text]
6. Prevalence of 9p21 deletions in UK melanoma families.
   Genes Chromosomes Cancer, 44(3): 292-300. [Abstract] [Full-text]
7. Association between endothelin receptor B nonsynonymous variants and melanoma risk.
   J Natl Cancer Inst, 97(17): 1297-301. [Abstract] [Full-text]
8. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome.
   Am J Clin Pathol, 124(4): 528-36. [Abstract] [Full-text]
9. Selectively desulfated heparin inhibits P-selectin-mediated adhesion of human melanoma cells.
   Cancer Lett, 229(1): 123-6. [Abstract] [Full-text]
10. Mapping of a novel ocular and cutaneous malignant melanoma susceptibility locus to chromosome 9q21.32.
    J Natl Cancer Inst, 97(18): 1377-82. [Abstract] [Full-text]
11. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma.
    Int J Cancer, 117(4): 596-604. [Abstract] [Full-text]
12. The melanoma-associated 24 base pair duplication in p16INK4a is functionally impaired.
    Int J Cancer, 117(4): 569-73. [Abstract] [Full-text]
13. Etiologic factors associated with p53 immunostaining in cutaneousmalignant melanoma.
    Int J Cancer, 117(3): 486-93. [Abstract] [Full-text]
14. An analysis of variability in the manufacturing of dexosomes: implications for development of an autologous therapy.
    Biotechnol Bioeng, 92(2): 238-49. [Abstract] [Full-text]
15. Dual mode reflectance and fluorescence confocal laser scanning microscopy for in vivo imaging melanoma progression in murine skin.
    J Invest Dermatol, 125(4): 798-804. [Abstract] [Full-text]
16. Increasing incidence of lentigo maligna melanoma subtypes: northern California and national trends 1990-2000.
    J Invest Dermatol, 125(4): 685-91. [Abstract] [Full-text]
17. Low-dose IL-2 induces cytokine cascade, eosinophilia, and a transient Th2 shift in melanoma patients.
    Cancer Immunol Immunother, 54(11): 1095-105. [Abstract] [Full-text]
18. Population-based analysis of prognostic factors and survival in familial melanoma.
    J Clin Oncol, 23(28): 7168-77. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.